136 related articles for article (PubMed ID: 16331622)
1. Serological analysis of human renal cell carcinoma.
Devitt G; Meyer C; Wiedemann N; Eichmüller S; Kopp-Schneider A; Haferkamp A; Hautmann R; Zöller M
Int J Cancer; 2006 May; 118(9):2210-9. PubMed ID: 16331622
[TBL] [Abstract][Full Text] [Related]
2. Serological identification of antigens associated with renal cell carcinoma.
Koroleva EP; Lagarkova MA; Mesheryakov AA; Scanlan MJ; Old LJ; Nedospasov SA; Kuprash DV
Russ J Immunol; 2002 Oct; 7(3):229-38. PubMed ID: 12674932
[TBL] [Abstract][Full Text] [Related]
3. Antigens recognized by autologous antibody in patients with renal-cell carcinoma.
Scanlan MJ; Gordan JD; Williamson B; Stockert E; Bander NH; Jongeneel V; Gure AO; Jäger D; Jäger E; Knuth A; Chen YT; Old LJ
Int J Cancer; 1999 Nov; 83(4):456-64. PubMed ID: 10508479
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis.
Klade CS; Voss T; Krystek E; Ahorn H; Zatloukal K; Pummer K; Adolf GR
Proteomics; 2001 Jul; 1(7):890-8. PubMed ID: 11503213
[TBL] [Abstract][Full Text] [Related]
5. [Human esophageal carcinoma antigens screened by serologic analysis of recombinant cDNA expression libraries (SEREX)].
Yu L; Hu H; Ran YL; Peng LP; Li JW; Yang ZH
Ai Zheng; 2007 Jan; 26(1):100-5. PubMed ID: 17222377
[TBL] [Abstract][Full Text] [Related]
6. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
[TBL] [Abstract][Full Text] [Related]
7. Tumor associated antigen recognition by autologous serum in patients with breast cancer.
Qian F; Odunsi K; Blatt LM; Scanlan MJ; Mannan M; Shah N; Montgomery J; Haddad F; Taylor M
Int J Mol Med; 2005 Jan; 15(1):137-44. PubMed ID: 15583840
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA).
Lagarkova MA; Koroleva EP; Kuprash DV; Boitchenko VE; Kashkarova UA; Nedospasov SA; Shebzukhov YV
Immunol Lett; 2003 Jan; 85(1):71-4. PubMed ID: 12505200
[TBL] [Abstract][Full Text] [Related]
9. Serological identification of tumor antigens of esophageal squamous cell carcinoma.
Shimada H; Nakashima K; Ochiai T; Nabeya Y; Takiguchi M; Nomura F; Hiwasa T
Int J Oncol; 2005 Jan; 26(1):77-86. PubMed ID: 15586227
[TBL] [Abstract][Full Text] [Related]
10. Serological detection of cutaneous T-cell lymphoma-associated antigens.
Eichmuller S; Usener D; Dummer R; Stein A; Thiel D; Schadendorf D
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):629-34. PubMed ID: 11149944
[TBL] [Abstract][Full Text] [Related]
11. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Hauser T; Schmitt A; Döhner H; Schmitt M
Int J Cancer; 2003 Aug; 106(2):224-31. PubMed ID: 12800198
[TBL] [Abstract][Full Text] [Related]
12. Mitofilin and titin as target antigens in melanoma-associated retinopathy.
Pföhler C; Preuss KD; Tilgen W; Stark A; Regitz E; Fadle N; Pfreundschuh M
Int J Cancer; 2007 Feb; 120(4):788-95. PubMed ID: 17131336
[TBL] [Abstract][Full Text] [Related]
13. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
14. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy.
Hartmann TB; Bazhin AV; Schadendorf D; Eichmüller SB
Int J Cancer; 2005 Mar; 114(1):88-93. PubMed ID: 15523688
[TBL] [Abstract][Full Text] [Related]
15. Frequency and gene expression profile of regulatory T cells in renal cell carcinoma.
Jeron A; Pfoertner S; Bruder D; Geffers R; Hammerer P; Hofmann R; Buer J; Schrader AJ
Tumour Biol; 2009; 30(3):160-70. PubMed ID: 19609102
[TBL] [Abstract][Full Text] [Related]
16. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
17. The reverse proteomics for identification of tumor antigens.
Lee SY; Jeoung D
J Microbiol Biotechnol; 2007 Jun; 17(6):879-90. PubMed ID: 18050904
[TBL] [Abstract][Full Text] [Related]
18. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
20. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma.
Teratani T; Domoto T; Kuriki K; Kageyama T; Takayama T; Ishikawa A; Ozono S; Nozawa R
Urology; 2007 Feb; 69(2):236-40. PubMed ID: 17320655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
